Clinical trials
Osteosarcoma clinical trials
Below are recruiting osteosarcoma clinical trials, each written for real people, not researchers. We’re tracking 76 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07321912RecruitingPhase 2
Eflornithine (DFMO) for Ewing sarcoma and osteosarcoma
This trial tests a drug called eflornithine (DFMO) for people with Ewing sarcoma or osteosarcoma that has come back or spread. The goal is to see if DFMO can help control the cancer after standard treatment.
Tampa, FloridaAges birth–50 years - NCT06892678RecruitingPhase 1/Phase 2
DFMO maintenance for relapsed Ewing sarcoma or osteosarcoma
This trial tests a drug called DFMO given as maintenance therapy to keep cancer from coming back. It is for people under 40 who have finished treatment for relapsed Ewing sarcoma or osteosarcoma and currently show no signs of cancer.
The Bronx, New YorkAges Up to 39 years - NCT06384404Recruiting
Surgery First for Osteosarcoma of the Arm or Leg
This trial tests removing the tumor with surgery first, then following up with chemotherapy. It's for people with a new, high-grade osteosarcoma in an arm or leg that hasn't spread.
The Bronx, New YorkAges 5–40 - NCT06017518Recruiting
Watching local relapse after high-grade osteosarcoma treatment
This study is watching people whose high-grade osteosarcoma came back in the same bone area (local relapse) after treatment. It helps doctors understand how local relapse happens, so they can improve future care.
Bologna, BOAges Any age - NCT06064682Recruiting
Organoid test to guide osteosarcoma treatment
This trial uses a lab-grown mini tumor (organoid) from your biopsy to test which drugs might work best for your osteosarcoma. It aims to personalize your treatment based on how your specific cancer cells respond.
Los Angeles, CaliforniaAges Any age - NCT05588648RecruitingPhase 1/Phase 2
Vactosertib for recurrent or progressive bone cancer
This trial tests a new drug called vactosertib for people with a type of bone cancer called osteosarcoma that has come back or hasn't responded to other treatments. The goal is to see if the drug can help shrink or slow the cancer and to check its safety.
Cleveland, OhioAges 12 years+ - NCT04901702RecruitingPhase 1/Phase 2
Onivyde plus talazoparib or temozolomide for resistant solid tumors
This trial tests whether adding Onivyde to either talazoparib or temozolomide can shrink or control hard-to-treat (refractory or recurring) cancers in children and young adults. It aims to find safer dosing first, then look at how well the treatment works—especially for Ewing sarcoma.
Palo Alto, CaliforniaAges 1–30 - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Birmingham, AlabamaAges 1–30 - NCT03900793RecruitingPhase 1
Losartan and sunitinib for advanced osteosarcoma
This trial tests a combination of two drugs, losartan and sunitinib, in people with osteosarcoma that has come back or spread after prior treatment. The study aims to see if this combination is safe and effective.
Los Angeles, CaliforniaAges 10 years+ - NCT03721068RecruitingPhase 1
CAR T-cell treatment for hard-to-treat childhood tumors
This Phase 1 study tests an experimental CAR T-cell treatment that targets GD2, with added immune-boosting and safety features, for children with relapsed or refractory neuroblastoma or osteosarcoma. It’s designed to see if the treatment is safe and can shrink these cancers when standard therapy hasn’t worked.
Atlanta, GeorgiaAges 1.5 years+ - NCT04758000RecruitingPhase 2
Metformin after bone cancer treatment to prevent relapse
This Phase 2 study tests whether taking metformin after surgery and chemotherapy can reduce the risk of bone cancer coming back in people at high risk of relapse. You may be eligible if you have osteosarcoma or Ewing sarcoma that is not currently spread and you meet specific lab and health criteria.
BolognaAges 14 years+ - NCT05328258RecruitingPhase 3
Triptorelin to help protect fertility during cancer chemotherapy
This Phase 3 study tests whether a hormone medicine called triptorelin (a GnRH “fertility-protecting” medicine) can better protect ovarian function while you receive chemotherapy. The goal is to help preserve fertility and reduce the risk of early ovarian failure from cancer treatment.
GothenburgAges 14–42 - NCT02013336RecruitingPhase 1
Two-drug study for returning childhood solid tumors
This study tests a combination of two drugs, MM-398 and cyclophosphamide, for children and young adults whose cancer has come back or not responded to earlier treatment. The goal is to find the best dose and see how well it works against certain tumor types.
Cincinnati, OhioAges 1–20 - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT06324916Recruiting
Long-term effects after fibula bone graft
This study looks at long-term effects at the donor site (where the bone was taken) after a fibula graft. It helps doctors understand how well patients recover from this surgery.
AsyutAges 18 years+ - NCT06029218Recruiting
Comparing one vs two proton beams for bone and spine tumors
This trial is testing whether using only one proton beam per day is as safe and effective as using two beams for treating certain bone and spine tumors. It may help reduce treatment time and side effects.
NiceAges 18 years+ - NCT07648069RecruitingPhase 1
Personalized Cancer Vaccine Plus Immune Cell Therapy for Advanced Sarcoma
This study tests a personalized vaccine made from your tumor's unique mutations, combined with special immune cells grown from your blood, to treat advanced sarcoma (bone or soft tissue cancer) that did not respond to initial treatment. The goal is to help your immune system recognize and attack cancer cells.
Guangzhou, GuangdongAges 18–70 - NCT07628634RecruitingEarly Phase 1
Testing a Low-Methionine Diet in Solid Tumor Patients
This early-stage study explores whether eating a diet low in methionine (a natural amino acid found in protein) might help people with advanced solid tumors. Researchers will track how this dietary change affects blood levels and may improve treatment outcomes alongside standard cancer care.
Orange, CaliforniaAges 18 years+ - NCT07596693RecruitingPhase 1
KXV01 injection for advanced solid tumors
This early-stage trial tests KXV01, a personalized cancer treatment made from your own immune cells, for advanced solid tumors that have not responded to standard treatment. The goal is to see if it can help control your cancer and learn about its safety.
ShanghaiAges 18–70 - NCT07602049RecruitingPhase 2
Freezing Plus Immunotherapy for Advanced Soft Tissue Sarcoma
This trial combines cryoablation (a freezing technique to destroy tumors) with camrelizumab (an immunotherapy drug that helps your immune system fight cancer) for patients with advanced soft tissue sarcoma that hasn't responded to standard treatments. The goal is to see if this combination works better than current options.
Guangzhou, GuangdongAges 14–70 - NCT07514819Recruiting
Adaptive Proton Therapy Planning for Children With Cancer
This study tests a new way to plan proton radiation therapy (a precise type of cancer treatment) for children with solid tumors or Hodgkin's lymphoma. The goal is to improve how doctors adapt treatment during therapy to better target tumors while protecting healthy tissue.
Memphis, TennesseeAges Any age - NCT07222735RecruitingPhase 1
CAR T cells and radiation for children with sarcoma
This trial tests a combination of targeted radiation and special immune cells (CAR T cells) for children and young adults whose bone or soft tissue sarcoma has come back or not responded to standard treatments. The CAR T cells are made from your own blood cells and are designed to attack a protein called B7-H3 found on the sarcoma cells.
Memphis, TennesseeAges Up to 21 years - NCT06935864Recruiting
Study of KLF4 and KLF7 in bone tumors
This study looks at two proteins, KLF4 and KLF7, in bone tumor samples. It aims to understand their role in osteosarcoma and Ewing sarcoma, which may help develop better treatments.
CairoAges 1 month–39 years - NCT07129226Recruiting
Smartwatch monitoring for leg and pelvis cancer recovery
This study uses a smartwatch to monitor your activity and recovery after treatment for sarcoma or bone cancer in your leg or pelvis. It helps your care team keep track of how you're doing from home.
Cleveland, OhioAges 18 years+
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for osteosarcoma?
- Yes. Clin2 currently lists 76 recruiting osteosarcoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a osteosarcoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a osteosarcoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.